We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
-0.88%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$227M
AUM Growth
-$15.9M
Cap. Flow
-$6.57M
Cap. Flow %
-2.89%
Top 10 Hldgs %
7.9%
Holding
407
New
8
Increased
60
Reduced
329
Closed
10

Top Buys

Rank Stock Value
1
XFLT
XAI Floating Rate & Alternative Income Trust
XFLT
+$689K
2
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
+$551K
3
FRA icon
BlackRock Floating Rate Income Strategies Fund
FRA
+$468K
4
ENIC icon
Enel Chile
ENIC
+$430K
5
EFT
Eaton Vance Floating-Rate Income Trust
EFT
+$429K

Top Sells

Rank Stock Value
1
GRA
W.R. Grace & Co.
GRA
+$1.73M
2
BGX
Blackstone Long-Short Credit Income Fund
BGX
+$731K
3
BGB
Blackstone Strategic Credit 2027 Term Fund
BGB
+$693K
4
NOA
North American Construction
NOA
+$554K
5
MCI
Barings Corporate Investors
MCI
+$524K

Sector Composition

Rank Sector Weight
1 Healthcare 25.28%
2 Real Estate 19.7%
3 Energy 13.28%
4 Utilities 12%
5 Materials 10.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDTX icon
351
Black Diamond Therapeutics
BDTX
$97.4M
$140K 0.06%
16,600
-862
-5% -$8.51K
FATE icon
352
Fate Therapeutics
FATE
$282M
$140K 0.06%
2,356
-130
-5% -$10.2K
STOK icon
353
Stoke Therapeutics
STOK
$1.86B
$140K 0.06%
5,502
-284
-5% -$7.92K
IBRX icon
354
ImmunityBio
IBRX
$7.32B
$139K 0.06%
14,244
-738
-5% -$8.12K
VSTM icon
355
Verastem
VSTM
$538M
$138K 0.06%
3,746
-195
-5% -$7.16K
DNTH icon
356
Dianthus Therapeutics
DNTH
$5.82B
$136K 0.06%
1,169
-61
-5% -$7.11K
CDAK
357
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$136K 0.06%
8,316
-439
-5% -$7.85K
RCKT icon
358
Rocket Pharmaceuticals
RCKT
$342M
$135K 0.06%
4,506
-228
-5% -$8.3K
MRSN
359
DELISTED
Mersana Therapeutics
MRSN
$134K 0.06%
567
-29
-5% -$8.47K
RYTM icon
360
Rhythm Pharmaceuticals
RYTM
$7.38B
$134K 0.06%
10,229
-536
-5% -$8.19K
RUBY
361
DELISTED
Rubius Therapeutics, Inc
RUBY
$134K 0.06%
7,478
-390
-5% -$8.48K
KALV
362
DELISTED
KalVista Pharmaceuticals
KALV
$131K 0.06%
7,494
-399
-5% -$8.09K
TCRT icon
363
Alaunos Therapeutics
TCRT
$4.69M
$131K 0.06%
480
-26
-5% -$7.95K
GMDA
364
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$130K 0.06%
33,121
-1,721
-5% -$8.6K
TARS icon
365
Tarsus Pharmaceuticals
TARS
$2.54B
$129K 0.06%
6,008
-311
-5% -$7.7K
MRNS
366
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$129K 0.06%
11,335
-595
-5% -$8.18K
BCEL
367
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$128K 0.06%
20,473
-1,077
-5% -$7.18K
ADVM
368
DELISTED
Adverum Biotechnologies
ADVM
$125K 0.06%
5,777
-302
-5% -$7.71K
GTHX
369
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$125K 0.06%
9,343
-489
-5% -$7.97K
ATNX
370
DELISTED
Athenex, Inc. Common Stock
ATNX
$125K 0.06%
2,072
-108
-5% -$7.86K
TECX
371
Tectonic Therapeutic
TECX
$555M
$124K 0.05%
1,854
-96
-5% -$7.88K
CVAC
372
DELISTED
CureVac
CVAC
$117K 0.05%
2,150
-109
-5% -$6.57K
DRNA
373
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$113K 0.05%
5,581
-299
-5% -$8.26K
AMTI
374
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$112K 0.05%
4,332
-233
-5% -$7.38K
CVM icon
375
CEL-SCI Corp
CVM
$20.4M
$109K 0.05%
332
-17
-5% -$4.96K
13 14
15
16 17

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q3 2021 Portfolio in Review

As of Q3 2021, Virtus ETF Advisers held 407 positions worth $227M, down 6.5% from $243M the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.

Trading was light in Q3 2021: portfolio turnover was 4.4%. Virtus ETF Advisers opened 8 new positions and exited 10, leaving the 407-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 27% a quarter earlier, followed by Real Estate and Energy.

  • Virtus ETF Advisers's largest Q3 2021 buy was XAI Floating Rate & Alternative Income Trust: 15,447 shares worth $663K.
  • Virtus ETF Advisers added most to Enel Chile in Q3 2021, an estimated $430K increase.
  • Virtus ETF Advisers's biggest Q3 2021 reduction was North American Construction, cutting an estimated $554K.
  • Virtus ETF Advisers fully exited W.R. Grace & Co. in Q3 2021, selling an estimated $1.73M.
  • Virtus ETF Advisers's ten largest holdings make up 7.9% of its $227M portfolio in Q3 2021.
  • Virtus ETF Advisers opened 8 new positions and closed 10 in Q3 2021.
  • Virtus ETF Advisers's portfolio value fell 6.5% quarter-over-quarter to $227M.

Based on Virtus ETF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.